{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:38:00Z","timestamp":1792874280217,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bbrc.2026.154684","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:59:50Z","timestamp":1791039590000},"page":"154684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["ZSP1601 is a non-selective phosphodiesterase inhibitor and a clinical drug candidate for the oral treatment of metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1016","volume":"839","author":[{"given":"Miao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuowei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bbrc.2026.154684_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinme.2025.100526","article-title":"Metabolic dysfunction-associated steatotic liver disease","volume":"25","author":"Hsu","year":"2025","journal-title":"Clin. Med."},{"issue":"3","key":"10.1016\/j.bbrc.2026.154684_bib2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","article-title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"24","author":"Do","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2026.154684_bib3","series-title":"MASH Clinical Trials and Drugs Pipeline: an Impending Tsunami, Hepatology","author":"Noureddin","year":"2024"},{"issue":"15","key":"10.1016\/j.bbrc.2026.154684_bib4","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/CM9.0000000000003629","article-title":"MASLD development: from molecular pathogenesis toward therapeutic strategies","volume":"138","author":"Yang","year":"2025","journal-title":"Chin. Med. J. (Engl. Ed.)"},{"issue":"10","key":"10.1016\/j.bbrc.2026.154684_bib5","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/s41423-025-01307-5","article-title":"Immunopathogenic mechanisms and immunoregulatory therapies in MASLD","volume":"22","author":"He","year":"2025","journal-title":"Cell. Mol. Immunol."},{"issue":"24","key":"10.1016\/j.bbrc.2026.154684_bib6","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in compensated liver cirrhosis caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bbrc.2026.154684_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jhep.2024.03.014","article-title":"Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis","volume":"81","author":"Yashaswini","year":"2024","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.bbrc.2026.154684_bib9","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.bbrc.2026.154684_bib10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11901-018-0425-7","article-title":"Pathogenesis of NASH: the impact of multiple pathways","volume":"17","author":"Noureddin","year":"2018","journal-title":"Curr. Hepat. Rep."},{"issue":"7","key":"10.1016\/j.bbrc.2026.154684_bib11","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12962-026-00741-0","article-title":"Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis","volume":"24","author":"Njei","year":"2026","journal-title":"Cost Eff. Resour. Allocation"},{"issue":"2","key":"10.1016\/j.bbrc.2026.154684_bib13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med. Res. Rev."},{"issue":"18","key":"10.1016\/j.bbrc.2026.154684_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810616","article-title":"The complexity and multiplicity of the specific cAMP phosphodiesterase family: PDE4, open new adapted therapeutic approaches","volume":"23","author":"Lugnier","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154684_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cellsig.2018.06.005","article-title":"Role of cAMP and phosphodiesterase signaling in liver health and disease","volume":"49","author":"Wahlang","year":"2018","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1465-9921-5-4","article-title":"The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma","volume":"5","author":"Clayton","year":"2004","journal-title":"Respir. Res."},{"issue":"8","key":"10.1016\/j.bbrc.2026.154684_bib17","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/mnfr.201500016","article-title":"Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway","volume":"59","author":"Zhang","year":"2015","journal-title":"Mol. Nutr. Food Res."},{"issue":"3","key":"10.1016\/j.bbrc.2026.154684_bib18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/fcp.12530","article-title":"Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats","volume":"34","author":"El-Deen","year":"2020","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"23","key":"10.1016\/j.bbrc.2026.154684_bib19","first-page":"8644","article-title":"Pentoxifylline and its association with kaempferol improve NASH-associated manifestations in mice through anti-apoptotic, anti-necroptotic, antioxidant, and anti-inflammatory mechanisms","volume":"26","author":"Hamouda","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.bbrc.2026.154684_bib20","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3748\/wjg.v20.i2.569","article-title":"Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis","volume":"20","author":"Du","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2165\/00003495-198734010-00003","article-title":"A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy","volume":"34","author":"Ward","year":"1987","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib22","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1038\/s41467-023-42162-0","article-title":"ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD: a randomized, placebo-controlled phase Ib\/IIa trial","volume":"14","author":"Hu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154684_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106808","article-title":"Dose finding for ZSP1601 in patients with nonalcoholic steatohepatitis using population pharmacokinetics and exposure-response approach","volume":"199","author":"Li","year":"2024","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.bbrc.2026.154684_bib24","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41467-024-44874-3","article-title":"Discovery of a peripheral 5HT2A antagonist as a clinical candidate for metabolic dysfunction-associated steatohepatitis","volume":"15","author":"Pagire","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154684_bib26","series-title":"Product Development Under the Animal Rule Guidance for Industry","year":"2015"},{"issue":"11","key":"10.1016\/j.bbrc.2026.154684_bib27","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.1021\/acs.jmedchem.1c00261","article-title":"The medicinal chemistry of caffeine","volume":"64","author":"Faudone","year":"2021","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bbrc.2026.154684_bib28","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.str.2004.10.004","article-title":"Structural basis for the activity of drugs that inhibit phosphodiesterases","volume":"12","author":"Card","year":"2004","journal-title":"Structure"},{"key":"10.1016\/j.bbrc.2026.154684_bib29","author":"Wu"},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/jps.2600750111","article-title":"Pharmacokinetics of orally administered pentoxifylline in humans","volume":"75","author":"Smith","year":"1986","journal-title":"J. Pharmaceut. Sci."},{"issue":"3","key":"10.1016\/j.bbrc.2026.154684_bib31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1684\/ecn.2012.0313","article-title":"TNF-alpha messenger ribonucleic acid (mRNA) in patients with nonalcoholic steatohepatitis","volume":"23","author":"Alaaeddine","year":"2012","journal-title":"Eur. Cytokine Netw."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib32","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1038\/s41467-024-50660-y","article-title":"A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma","volume":"15","author":"Jeong","year":"2024","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bbrc.2026.154684_bib33","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1248\/bpb.b19-00338","article-title":"Reduced serum cholesterol and triglyceride levels in a choline-deficient L-Amino acid-defined high-fat diet (CDAHFD)-Induced mouse model of non-alcoholic steatohepatitis (NASH)","volume":"43","author":"Yasuda","year":"2020","journal-title":"Biol. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib34","article-title":"Mangiferin relieves CCl4-induced liver fibrosis in mice","volume":"13","author":"Zhang","year":"2023","journal-title":"Sci. Rep.-Uk"},{"key":"10.1016\/j.bbrc.2026.154684_bib35","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/labinvest.2010.123","article-title":"State that Kupffer cells are associated with apoptosis, inflammation, and fibrotic effects in hepatic fibrosis in rats","volume":"90","author":"Liu","year":"2010","journal-title":"Lab. Invest."},{"issue":"6","key":"10.1016\/j.bbrc.2026.154684_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03242-22","article-title":"Transcriptome and gut microbiota profiling analysis of ANIT-Induced cholestasis and the effects of da-huang-xiao-shi decoction intervention","volume":"10","author":"Wang","year":"2022","journal-title":"Microbiol. Spectr."},{"issue":"2","key":"10.1016\/j.bbrc.2026.154684_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/08982100903161456","article-title":"Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles","volume":"20","author":"Varshosaz","year":"2010","journal-title":"J. Liposome Res."},{"issue":"6","key":"10.1016\/j.bbrc.2026.154684_bib38","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2460\/ajvr.2000.61.631","article-title":"Pharmacokinetics of pentoxifylline in dogs after oral and intravenous administration","volume":"61","author":"Marsella","year":"2000","journal-title":"Am. J. Vet. Res."},{"issue":"4","key":"10.1016\/j.bbrc.2026.154684_bib39","article-title":"Mannose reduces fructose metabolism and reverses MASH in human liver slices and murine models in vivo, Hepatol","volume":"9","author":"Hong","year":"2025","journal-title":"Commun. Now."},{"key":"10.1016\/j.bbrc.2026.154684_bib40","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.2147\/DDDT.S530855","article-title":"Butein alleviates non-alcoholic steatohepatitis in leptin-deficient mice by modulating the PDE4\/cAMP\/p-CREB pathway","volume":"19","author":"Guo","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bbrc.2026.154684_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150170","article-title":"Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob\/ob mice","volume":"722","author":"Wang","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.bbrc.2026.154684_bib42","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1097\/HEP.0000000000000999","article-title":"A novel phosphodiesterase inhibitor for the treatment of chronic liver injury and metabolic diseases","volume":"81","author":"Staller","year":"2025","journal-title":"Hepatology"},{"issue":"Pt 3","key":"10.1016\/j.bbrc.2026.154684_bib43","article-title":"A novel phosphodiesterase 5 inhibitor, CPD1, alleviates liver fibrosis by modulating the Akt\/NF-\u03baB pathway to inhibit activated hepatic stellate cells","volume":"242","author":"Feng","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-67305-1","article-title":"Ameliorative effects of sildenafil against carbon tetrachloride induced hepatic fibrosis in rat model through downregulation of osteopontin gene expression","volume":"14","author":"Nasr","year":"2024","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.bbrc.2026.154684_bib45","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1139\/cjpp-2018-0338","article-title":"The anti-inflammatory and anti-fibrotic effects of tadalafil in thioacetamide-induced liver fibrosis in rats, can","volume":"96","author":"Mansour","year":"2018","journal-title":"J. Physiol. Pharmacol."},{"issue":"10","key":"10.1016\/j.bbrc.2026.154684_bib46","doi-asserted-by":"crossref","first-page":"8309","DOI":"10.1021\/acs.jmedchem.4c00461","article-title":"Design, synthesis, and evaluation of dihydropyrimidine derivatives as selective PDE1 inhibitors for the treatment of liver fibrosis","volume":"67","author":"Zhao","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2026.154684_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2026.102433","article-title":"Mitochondrial NCLX couples glucagon- and PDE2A-dependent signals to regulate hepatic lipid metabolism","author":"Assali","year":"2026","journal-title":"Mol. Metabol."},{"issue":"9","key":"10.1016\/j.bbrc.2026.154684_bib48","first-page":"802","article-title":"Pipeline of new drug treatment for non-alcoholic fatty liver disease\/metabolic dysfunction-associated steatotic liver disease","volume":"12","author":"Hu","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.bbrc.2026.154684_bib49","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/1043-4666(90)90032-O","article-title":"The effects of pentoxifylline on lipopolysaccharide (LPS) fever, plasma interleukin 6 (IL-6), and tumor necrosis factor (TNF) in the rat","volume":"2","author":"LeMay","year":"1990","journal-title":"Cytokine"},{"key":"10.1016\/j.bbrc.2026.154684_bib50","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1007\/s10620-006-9723-y","article-title":"Effects of pentoxifylline on TNF-alpha production by peripheral blood mononuclear cells in patients with nonalcoholic steatohepatitis","volume":"52","author":"Duman","year":"2007","journal-title":"Dig. Dis. Sci."},{"issue":"5","key":"10.1016\/j.bbrc.2026.154684_bib51","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.bbrc.2026.154684_bib52","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/j.1572-0241.2004.40064.x","article-title":"A pilot trial of pentoxifylline in nonalcoholic steatohepatitis","volume":"99","author":"Adams","year":"2004","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/0091270011433435","article-title":"Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation","volume":"53","author":"Nisi","year":"2013","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.bbrc.2026.154684_bib54","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1172\/JCI117899","article-title":"The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase","volume":"95","author":"Kern","year":"1995","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.bbrc.2026.154684_bib55","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.cld.2004.04.012","article-title":"Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease","volume":"8","author":"Diehl","year":"2004","journal-title":"Clin. Liver Dis."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib56","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.20280","article-title":"Beyond insulin resistance in NASH: TNF-alpha or adiponectin?","volume":"40","author":"Hui","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2026.154684_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104714","article-title":"Alterations of hepatic energy metabolism in murine models of obesity, diabetes, and fatty liver diseases","volume":"94","author":"Dewidar","year":"2023","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib58","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1186\/s12885-024-13136-2","article-title":"Early-life antibiotic exposure aggravates the metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma","volume":"24","author":"Tian","year":"2024","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.bbrc.2026.154684_bib59","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/iep.12008","article-title":"An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis","volume":"94","author":"Matsumoto","year":"2013","journal-title":"Int. J. Exp. Pathol."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib60","doi-asserted-by":"crossref","first-page":"G51","DOI":"10.1152\/ajpgi.00110.2024","article-title":"Characterization of six clinical drugs and dietary intervention in the nonobese CDAA-HFD mouse model of MASH and progressive fibrosis","volume":"328","author":"Nielsen","year":"2025","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbrc.2026.154684_bib61","article-title":"Hepatocyte-, but not myeloid cell-Rictor\/mTORC2 deficiency moderately attenuates steatotic liver disease induced by intake of a choline-deficient, amino acid-defined high-fat diet","author":"Leonardi","year":"2026","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib62","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1124\/jpet.113.204933","article-title":"Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4","volume":"347","author":"Gobejishvili","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib63","doi-asserted-by":"crossref","DOI":"10.1172\/JCI182571","article-title":"Selective inhibition of long isoforms of phosphodiesterase 4D mitigates liver fibrosis in mouse models","volume":"136","author":"Kim","year":"2026","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib64","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1172\/JCI88881","article-title":"Liver inflammation and fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010382","article-title":"Exosomal miRNAs as potential biomarkers to monitor phosphodiesterase 5 inhibitor induced anti-fibrotic effects on CCl4-treated rats","volume":"22","author":"Broermann","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154684_bib66","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.14103","article-title":"sGC stimulator (BAY 41-8543) combined with PDE9 inhibitor (BAY 73-6691) reduces renal fibrosis in 5\/6 nephrectomized rats","volume":"136","author":"Chen","year":"2025","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.bbrc.2026.154684_bib67","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fphar.2017.00256","article-title":"SRT1720 alleviates ANIT-induced cholestasis in a mouse model","volume":"8","author":"Yu","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.bbrc.2026.154684_bib68","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jhep.2024.01.036","article-title":"Sex-determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiology","volume":"80","author":"Wu","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2026.154684_bib69","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41421-025-00783-3","article-title":"Estrogen receptor 1 signaling in hepatic stellate cells designates resistance to liver fibrosis","volume":"11","author":"Li","year":"2025","journal-title":"Cell Discov."},{"issue":"6","key":"10.1016\/j.bbrc.2026.154684_bib70","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.coph.2011.09.003","article-title":"The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis","volume":"11","author":"Tsai","year":"2011","journal-title":"Curr. Opin. Pharmacol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2601449X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2601449X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:57:14Z","timestamp":1792871834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X2601449X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":70,"alternative-id":["S0006291X2601449X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154684","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ZSP1601 is a non-selective phosphodiesterase inhibitor and a clinical drug candidate for the oral treatment of metabolic dysfunction-associated steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154684"}}